SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

17 May 2026 Evaluate
The company witnessed a 23.24% growth in the revenue at Rs. 1326.65 millions for the quarter ended March 2026 as compared to Rs. 1076.48 millions during the year-ago period.Net Profit witnessed a 724.02% growth almost the double from Rs. 10.95 millions to Rs. 90.23  millions  of same quarter last year.The company reported a good operating profit of 261.66 millions compared to 91.98 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 1326.65 1076.48 23.24 4962.96 3664.15 35.45 4962.96 3664.15 35.45
Other Income -3.69 12.95 -128.49 35.28 35.61 -0.93 35.28 35.61 -0.93
PBIDT 261.66 91.98 184.47 928.58 294.05 215.79 928.58 294.05 215.79
Interest 14.38 3.88 270.62 28.51 12.90 121.01 28.51 12.90 121.01
PBDT 247.28 88.10 180.68 900.07 281.15 220.14 900.07 281.15 220.14
Depreciation 97.53 72.56 34.41 368.42 276.54 33.22 368.42 276.54 33.22
PBT 149.75 15.54 863.64 531.65 4.61 11432.54 531.65 4.61 11432.54
TAX 59.52 4.59 1196.73 140.83 1.34 10409.70 140.83 1.34 10409.70
Deferred Tax 33.82 4.73 615.01 40.16 1.32 2942.42 40.16 1.32 2942.42
PAT 90.23 10.95 724.02 390.82 3.27 11851.68 390.82 3.27 11851.68
Equity 233.92 233.92 0.00 233.92 233.92 0.00 233.92 233.92 0.00
PBIDTM(%) 19.72 8.54 130.83 18.71 8.03 133.15 18.71 8.03 133.15

Tatva Chintan Pharma Share Price

1185.65 6.00 (0.51%)
16-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
SRF 2742.15
BASF India 3455.30
Tata Chemicals 729.60
Pidilite Inds. 1571.05
Deepak Nitrite 1642.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: